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Abstract: The study objective was to determine the mechanical integrity and radiopacity
of regenerated bone within critical-sized defects (CSDs) in radii of rabbits using recombi-
nant human bone morphogenetic protein 2 (rhBMP-2) with a porous, biodegradable
poly(D,L-lactic acid) (PDLLA) carrier (designated PLA). Twenty millimeter, unilateral
radial ostectomies were created in 96 skeletally mature New Zealand white rabbits. The
rabbits were randomly assigned to six treatment groups with two euthanasia periods.
Treatment groups included unfilled defect (n Å 8), segmental autograft (n Å 8), PLA /
0 mg rhBMP-2 (n Å 8), PLA / 17 mg rhBMP-2 (n Å 8), PLA / 35 mg rhBMP-2 (n Å
8), and PLA / 70 mg rhBMP-2 (n Å 8). The radiopacity was significantly greater for
the 35- and 70-mg rhBMP-2 groups at 4 weeks compared to unfilled controls, PLA only, 
and 17-mg rhBMP-2 groups and equivalent to the autograft. At 8 weeks all groups receiv-
ing rhBMP-2 were equivalent to the autograft and significantly greater than unfilled 
defects and PLA alone. Similarly, the biomechanical analysis indicated significantly 
greater torque at failure for the 35-mg rhBMP-2 group compared to all other groups at 
4 weeks. By 8 weeks all groups receiving rhBMP-2 and autograft had significantly greater 
torque than unfilled controls and PLA alone. These radiomorphometric and biomechani-
cal results indicate PLA may be a suitable carrier for rhBMP-2 used for skeletal regenera-
tion. 
Keywords: bone morphogenetic protein; bone regeneration; critical size defect; rabbit;
biomechanics
INTRODUCTION major disadvantages of autografts are donor site morbidity
and limitations on the quantity of graft material.1,3,4 Allo-
Bone grafts have been used for decades to repair osseous grafts are often considered as an alternative to autografts.
discontinuities resulting from trauma, neoplasm resection, Although allografts do not contain viable cells at the time
and congenital abnormalities; and over 100 000 are per- of implantation, they serve as a scaffolding for revasculari-
formed each year in the United States.1,2 Autografts are zation and as a source for healing factors promoting osse-
most widely used by surgeons. These grafts contain viable ous ingrowth (i.e., osteoconduction). However, allografts
cells, bone marrow containing osteoprogenitor cells, and a have been associated with disease transmission and infec-
collagenous matrix that combine to form a favorable milieu tions.1,5–7 Additionally, common problems with allografts
for osteogenesis, osteoinduction, and osteoconduction. The include nonunions and delayed unions.1,8 Gross et al.9 re-
ported incomplete incorporation of allografts even as late
as 7 years. Neither autograft nor allograft provide the pa-
tient with ideal bone graft material. Consequently, there is
Correspondence to: Dr. D. L. Wheeler (e-mail: wheelerd@ortho.ufl.edu)
a strong clinical need to develop alternatives to autografts
Contract grant sponsor: NIH; contract grant number: R01- HD31451-2 and allografts.1,2 Hydroxyapatite (HA), tricalcium phos-
phate, and bioactive glasses have proven to be viable bone
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Figure 1. A graphical representation of the temporal changes and comparative changes in radiopacity
between treatment groups in the regenerating rabbit radii. The autograft and all rhBMP-2 filled defects
produced significantly more bone than unfilled defects and PLA-only groups by 4 weeks. The radio-
pacity measurements represent the mean of eight animals for each treatment group. A, unfilled defect;
B, segmental autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg rhBMP-2 / PLA; F, 70 mg
rhBMP-2 / PLA. (* ) B, D, E, F ú A, C (p õ 0.05). ( ** ) B ú A, C, D, E, F (p õ 0.05).
graft substitutes.10–16 These alloplastic materials vary in chanical integrity of the regenerated bone, and to compare
the rhBMP-2 regenerated bone to that of unfilled defectsporosity, granularity, size, and resorbability and typically
serve as a template or scaffold for osteoconduction within and autograft-filled defects. The hypotheses of the study
were that one of the doses of rhBMP-2 / PLA wouldthe bony defect. More recently, recombinant genetically
engineered bone growth proteins, such as bone morphogen- promote radiographic density similar to that of the ‘‘gold
standard’’ autograft and the biofunctionality promoted byetic proteins (BMPs) and transforming growth factor
b(TGFb) , were combined either with bioresorbable poly- one of the rhBMP-2 doses would be equivalent to that
promoted by the autograft.mers or calcium phosphate carriers and emerged as an
effective and promising osteoinductive bone graft alterna-
tive.17–20 Animal studies validated the efficacy and safety
of BMPs in regenerating non-load-bearing skeletal de- MATERIALS AND METHODS
fects.18,21–24 However, delivering the protein to skeletal de-
fect sites through use of an appropriate carrier has been a Ninety-six skeletally mature New Zealand white rabbits
challenging task. The most common BMP carriers investi- were randomly assigned to six treatments groups and two
gated include collagen sponges21,22 and biodegradable euthanasia periods (4 and 8 weeks) . Treatment groups
polymers.25,26 This study will use a biodegradable polymer included[poly(D,L lactic acid) (PDLLA) referred to as recombinant
human BMP-2 (rhBMP-2) / PLA] adsorbed with rhBMP- 1. unfilled defect (n Å 8),2 as a potential bone graft. Therefore, the purpose of this
2. segmental autograft (n Å 8),study was threefold: to regenerate critical-sized defects
3. PLA / 0 mg rhBMP-2 (n Å 8),(CSDs) in radii of rabbits with several varying doses of
rhBMP-2 / PLA, to assess radiographic density and me- 4. PLA / 17 mg rhBMP-2 (n Å 8),
649B/ 8h17$$649b 10-16-98 10:45:23 jbma W-JBM
incision was made and the tissues overlying the distal dia-
physeal radius were dissected. A 2-cm segmental defect
was created in the radius with a mini-oscillating saw using
copious sterile saline irrigation. The assigned treatment ma-
terial was placed in the bony defect. No internal fixation
was supplied because of the stabilization of the adjacent
ulna. The soft tissues were closed in layers using 4-0 Vicryl
sutures (Ethicon Inc., Somerville, NJ). The skin was closed
with surgical staples (Precise DS-25, 3M, St. Paul, MN).
Postoperative analgesia (Buprenex, 0.3 mg/mL, Reckitt
and Coleman Pharmaceuticals Inc., Richmond, VA) was
given as needed at a dose of 0.1 mL/kg. Water and food
were provided ad libidum.
Immediate postoperative lateral radiographs were taken
of the operative limb. Standardized radiographs were taken
immediately postoperatively, every 2 weeks in life, and at
sacrifice.
At sacrifice, the radius–ulna complex was disarticulated
Figure 2. Photographs illustrating changes in radiopacity between
at the elbow and wrist and specimens were stored at 020treatment groups at 8 weeks including the unfilled defect (CSD),
7C with tissue intact until torsional mechanical testing wassegmental autograft, 0 mg rhBMP-2 / PLA, 17 mg rhBMP-2 / PLA,
35 mg rhBMP-2 / PLA, and 70 mg rhBMP-2 / PLA. initiated. Torsional tests were preferable to bending tests
in this animal model in that they simulate clinically relevant
fracture patterns, apply equal loads to all sections of the
bone, and are relatively insensitive to specimen length and5. PLA / 35 mg rhBMP-2 (n Å 8), and
orientation.30,31 Bone fails in torsion at the weakest point6. PLA / 70 mg rhBMP-2 (n Å 8).
along the shaft.
Specimens were thawed to room temperature, the softThe PLA carrier used for rhBMP-2 was PDLLA. tissue was carefully removed, and the proximal and distalPDLLA was designed with high porosity to enhance
ends of the radius–ulna complex were potted in dental
adsorption of rhBMP-2 within the macrostructure.27 The plaster (0-67 Snow White Stone, Miles Inc., South Bend,polymer was manufactured into cylindrical formats (4.68 IN) in order to grip the specimen for testing. Transcortical1 20 mm). Highly purified rhBMP-218,28 was placed in
cuts were made in the ulna adjacent to the potted ends to
sterile glass vials containing a sodium glutamate buffer (5
eliminate the mechanical contribution of the ulna and iso-
mM, pH 4.5). At the time of surgery, 0.17 mL of buffer
late the radius during torsional testing. Separation of the
containing either 0, 17, 35, or 70 mg of rhBMP-2 was
ulna from the radius was not possible due to ulnar hypertro-transferred in a sterile fashion by syringe to the sterile PLA
phy, scar tissue formation, and fibrous fusion. Unpublisheddelivery vehicle.29 Immediately following the transfer of
preliminary experimentation indicates the discontinuousthe growth factor the rhBMP-2 / PLA was placed into the
ulna segment does not affect the breaking torque or stiff-ostectomy gap.
ness. The radius of the specimens was loaded to failure inThe rabbits were anesthetized using a mixture of 10 mL
torsion using a biaxial MTS MiniBionix materials testingof ketamine hydrochloride (Ketaset, USP, 100 mg/mL,
machine (MTS Inc., Minneapolis, MN) at a loading rateFort Dodge Laboratories, Inc., Fort Dodge, IA) and 5 mL
of 1807 /s.32 Data were collected at 1000 Hz for the durationof xylazine (Gemini SA, 20 mg/mL, Burns Veterinary Sup-
of the test. Values of ultimate torque (torque at failure)ply, Inc., Rockville Center, NY) at a dose of 0.65 mL/kg
and angular displacement at failure were extracted frombody weight. Triple antibiotic opthalmic ointment (Lacri-
the data. Specimen stiffness and energy absorbed duringlube, Allergen Pharmaceuticals, Irvine, CA) was applied
failure were calculated as the slope of the torque/angleto the rabbit’s eyes when anesthesized to prevent dryness.
curve and the area under the torque/angle curve, respec-Prophylatic antibiotics (Baytril, Miles Inc., Shawnee Mis-
tively.sion, KS) were administered preoperatively at a dose of
The biomechanical and radiomorphometric results were2.25 to 2.50 mg/kg. The operative site ( the left or right
analyzed using a 2-way analysis of variance (ANOVA) tofront limb) was shaved, prepped, and draped for aseptic
look at the effects of time (4 and 8 weeks) and treatmentsurgery with the rabbit in the supine position. A tourniquet
(A, B, C, D, E, and F). If significance was noted with thewas placed around the axillary region. The subcutaneous
ANOVA, a 1-way ANOVA was used to look at the effectsregion around the operative site was injected with 0.5 mL
of time by treatment and treatment by time followed by aof 2% Lidocaine with epinephrine 1:100,000 (Xylocaine,
Duncan’s multiple comparison procedure with a signifi-20 mg/mL, Astra Pharmaceutical Products Inc., Westbor-
ough, MA). An approximately 3-cm long superiomedial cance level set at p Å 0.05. Given the sample size, the
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Figure 3. Graphical representation of the breaking torque of the regenerating radii at 4 and 8 weeks.
The 35-mg rhBMP-2 was significantly greater than all other treatments at 4 weeks, yet by 8 weeks
the autograft and all BMP-2 treated groups were equivalent. The breaking torque measurements
represent the mean of eight animals for each treatment group. A, unfilled defect; B, segmental
autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg rhBMP-2 / PLA; F, 70 mg rhBMP-2 /
PLA. (* ) E ú A, B, C, D, F (p õ 0.05). ( ** ) B, D, E, F ú A, C (p õ 0.05).
statistical power of the analysis was 80% (SAS, Inc., Ver- (B, D, E, F ú A, C) was observed at 8 weeks (Fig. 1) .
sion 6.11, Cary, NC). All rhBMP-2 treated and autograft treated wounds revealed
complete bridging and complete radiopacity of the bridging
tissue by 8 weeks. A time-dependent effect was noted in
RESULTS the increase of opacity between the 2-week measurement
and the 4-, 6-, and 8-week measurement for the autograft
Radiomorphometry and all rhBMP-2 groups (groups B, D, E, and F) (p õ
0.05). The unfilled defect and PLA-only group (groups ARadiomorphometric analysis indicated the unfilled defect
and C) did not exhibit more opacity with time. The tempo-(group A) displayed radiolucent nonunion throughout the
ral changes in radiopacity can be visualized in the graph8-week study. Autograft sites revealed a radiolucent inter-
of Figure 1 and the composite radiographs of Figure 2.face bracketing the graft at 4 weeks that was less evident
PLA is radiolucent; therefore, the radiopacity of all groupsby 8 weeks. A slight radiopacity proximal and distal to a
except the segmental autograph group (group B) wereradiolucent midportion was observed for the unfilled de-
equivalent immediately postsurgery. At 2 weeks the 35-fects (group A) and the 0-mg rhBMP-2 / PLA cohort
and 70-mg rhBMP-2 groups (groups E and F) portrayed a(group C) at 4 and 8 weeks. The autograft and all rhBMP-
hint of radiopacity that increased and was equivalent to the2 filled defects (groups B, D, E, and F) produced equivalent
autograft (group B) by 4 weeks. At 6 weeks the highestamounts of regenerated bone by 4 weeks that was signifi-
doses of rhBMP-2 (groups E and F) portrayed a bonelikecantly more bone than the unfilled defects and PLA-only
groups (groups A and C) (p õ 0.05). The same pattern radiographic quality, yet by 8 weeks complete bridging
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Figure 4. Maximum angular displacement at failure of the regenerating radii at 4 and 8 weeks. All
treatment groups were equivalent at 4 weeks. Yet, by 8 weeks the angular displacement of the PLA-
only group was significantly greater than other groups. The angular displacement measurements
represent the mean of eight animals for each treatment group. A, unfilled defect; B, segmental
autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg rhBMP-2 / PLA; F, 70 mg rhBMP-2 /
PLA. (* ) C ú A, B, D, E, F (p õ 0.05).
and F) and the autograft group (group B) and significantlywas noted including cortical development. Groups A, C,
greater than the unfilled defects and PLA-only groupsD, E, and F were noted to have fringes of radiopacity that
(groups A and C). Although the magnitude of stiffnesswere localized near the host bone junction with no isolated
was greater at 8 weeks for all groups, the same trends wereradiopaque areas distant from the host bone.
noted (Fig. 5) .
The energy absorbed at failure was significantly greater
Biomechanics for the 35-mg rhBMP-2 / PLA group (group E) than all
other groups at 4 weeks but not greater than the autograft-The failure torque was significantly greater for the 35-mg
filled defects (group B) (p õ 0.05). However, by 8 weeksBMP treated animals (group E) than for all other treat-
the energy to failure for the autograft group (group B) wasments at 4 weeks. By 8 weeks the autograft (group B) and
significantly greater than all other groups. (Fig. 6) .all BMP treated animals (groups D, E, and F) had equiva-
lent breaking torque, yet the unfilled defects and PLA-only
defects (groups A and C) were significantly weaker
DISCUSSION(Fig. 3) .
The angular displacement at failure was not different
among the groups at 4 weeks. Yet by 8 weeks the angular The results of this radiomorphometric and biomechanical
study concur with our hypothesis: all doses (17, 35, anddisplacement of the PLA only (group C) was significantly
greater than all other groups (Fig. 4) . 70 mg rhBMP-2), used in conjunction with a PLA carrier,
were able to regenerate bone in a rabbit radius CSD withThe mechanical stiffness of the defects at 4 weeks was
equivalent for all rhBMP-2 treated groups (groups D, E, comparable mechanical strength and radiopacity to auto-
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Figure 5. Mechanical stiffness of the regenerating radii at 4 and 8 weeks. At both 4 and 8 weeks,
all rhBMP-2 treated groups and autograft had significantly greater stiffness than unfilled defects and
PLA-only groups. The stiffness measurements represent the mean of eight animals for each treatment
group. A, unfilled defect; B, segmental autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg
rhBMP-2 / PLA; F, 70 mg rhBMP-2 / PLA. (* ) B, D, E, F ú A, C (p õ 0.05).
graft-filled defects within 4 weeks of surgery. The rhBMP- between the 35- and 70-mg rhBMP-2 groups at 4 weeks
seen in the biomechanical data, and to a lesser extent in2 augmented defects healed significantly better than un-
filled defects or defects filled with only PLA. There was a the radiographic data, may simply be a stabilization process
of the physiological system. At the later time points, 6 and 8dose–response relationship of rhBMP-2 for radiopacity at
2 weeks, and the higher doses produced superior bone for- weeks for radiographic data and 8 weeks for biomechanical
data, the data follows classic dose–response behavior. Inmation than the lowest dose. The results of this biomechan-
ical study support our previously reported quantitative his- a separate experiment, a similar rhBMP-2 dose–response
was observed in the quantity of bone within the defect sitetomorphological findings indicating that rhBMP-2 and
PLA carrier can effectively regenerate bone in a dose– that was assessed histologically.29
The rhBMP-2 / PLA animals exhibited a significantresponse fashion at specific skeletal sites (rabbit radius) .29
The classic dose–response relationship was observed time-dependent increase in bone formation (radiopacity)
within the gap between 2 and 4 weeks. After 4 weeks noradiographically and biomechanically in rhBMP-2 treated
animals, especially at later time points. At early time points significant increase in bone within the defect was radio-
graphically noted for any experimental groups. This wouldthe response was more variable. The actions of BMP are
receptor mediated that would theoretically lead to a stan- indicate that rhBMP-2 effects are seen immediately by
stimulating early bone regeneration. The effects of localdard dose–response curve (plateau in response once the
receptors are saturated) . The temporal aspect of this study administration of rhBMP-2 would tend to diminish with
dissolution of rhBMP-2 concentration at the defect site.complicates the dose–response mechanism. In this in vivo
bone regeneration system, BMP also has autocrine and Although the mechanical strength at 2 weeks was not evalu-
ated, it would be estimated to parallel the increase in radio-paracrine functional components. The transient disparity
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Figure 6. Energy absorbed at failure of the regenerating radii at 4 and 8 weeks. The 35-mg rhBMP-
2 group had significantly higher energies at failure than all other treatment groups at 4 weeks except
the autograft group. However, by 8 weeks the autograft group had higher energies than all other
treatment groups. The energy measurements represent the mean of eight animals for each treatment
group. A, unfilled defect; B, segmental autograft; C, PLA only; D, 17 mg rhBMP-2 / PLA; E, 35 mg
rhBMP-2 / PLA; F, 70 mg rhBMP-2 / PLA. (* ) E, B ú A, C, D, F (p õ 0.05). ( ** ) B ú A, C, D, E, F
(p õ 0.05).
pacity. Histological assessment of bone formation rates bone is formed and therefore would have limited clinical
utility. Demineralized bone matrix produced inconsistentwithin the defect site would also confirm the time-depen-
dent effects of rhBMP-2 noted radiographically and is clinical results due to infection, immunologic rejection,
viral transmission, varying processing techniques and ster-planned for follow-up studies.
Although the use of rhBMPs for bone regeneration and ilization, and lack of continuity and structural integrity.34,35
There has been controversy over the biocompatibility anddevelopmental biology have been studied extensively,24,33
the use of PDLLA as a carrier for growth factors and/ use of poly(lactic acid) and poly(glycolic acid) within
skeletal defects.36,37 However, the material characteristicsor an osteoconductive template has not been previously
investigated. An appropriate delivery system is crucial to of these polymers holds great potential for use in skeletal
regeneration, specifically their ability to degrade in a repro-the overall effectiveness of the administered growth factor.
The delivery system is responsible for the localization of ducible and designated fashion (given the molecular weight
of polymeric components) with the potential for drug deliv-the growth factor, mesenchymal cell deposition and re-
tainment, and establishment of a template for contour and ery release with degradation. The polymer used for this
project, PDLLA (designated PLA) was custom designedstructural confinement of new bone growth.
In previous studies two classes of delivery systems for to have specific characteristics of degradation kinetics to
release rhBMP-2, which coincided with tissue regenerationrhBMPs were used: collagen based and poly(a-hydroxy
acids) .21,22 HA, HA-tricalcium phosphate, and demineral- within the defect.38
The mechanical strength of regenerated bone using poly-ized bone matrix were also used to deliver rhBMPs.16,18
Calcium phosphate delivery systems are either not biode- mer carriers and rhBMP-2 was recently published by Bos-
trom et al.39 Bostrom and colleagues evaluated rhBMP-2gradable or do not biodegrade at the same rate at which
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Autograft versus allograft for benign lesions in children. Clin.combined with polylactic glycolic acid porous micro-
Orthop. Rel. Res. 262:28–33; 1991.spheres and autologous blood in healing of a 2-cm ulnar 4. Laurie, S. W.; Kaban, L. B.; Mulliken, J. B.; Murray, J. E.defects in New Zealand white rabbits. They found a similar Donor-site morbidity after harvesting rib and iliac bone.
dose-dependent relationship as the current study between Plast. Reconstr. Surg. 73:933–938; 1984.
5. Buck, B. E.; Malinin, T. I. Bone transplantation and humanthe dose of rhBMP-2 and the mechanical strength of the
immunodeficency virus. An estimate of risk of acquired im-healed defects. Additionally, the optimal rhBMP-2 dose
munodeficiency syndrome. Clin. Orthop. Rel. Res. 260:129–(35–40 mg rhBMP-2) for bone regeneration concurs be- 136; 1989.tween the two studies. Both studies indicate that at this 6. Horowitz, M. C.; Friedlaender, G. E. Induction of specific T-
optimal dose of rhBMP-2, bone strength returned to normal cell responsiveness to allogenic bone. J. Bone Joint Surg.
73A:1157–1168; 1991.( intact limb) by 8 weeks.
7. Tomford, W. Current concepts review: transmission of dis-Other studies evaluated the strength of demineralized
ease through transplantation of musculoskeletal allografts. J.bone matrix and rhBMP-induced bone within defects using Bone Joint Surg. 77A:1742–1754; 1995.
collagenous carriers.40,41 Bolander and Balian found demin- 8. Enneking, W. F.; Mindell, E. R. Observations on massive
eralized bone matrix induced active woven bone formation retrieved human allografts. J. Bone Joint Surg. 73A:1123–
1142; 1991.within large ulnar defects in rabbits, yet the strength of the
9. Gross, A. E.; McKee, N. H.; Pritzker, K. P. H.; Langes, F.newly formed bone was 50% that of intact bone after 12
Reconstruction of skeletal deficits at the knee: a comprehen-weeks.40 Cook et al.41 used rhOP-1 (rhBMP-7) with a colla-
sive osteochondral transplant program. Clin. Orthop. Rel.gen carrier to fill ulnar defects in rabbits. At 8 weeks post- Res. 174:96–106; 1983.
operatively new bone had formed within the defect sites 10. Bostman, O. M. Current concepts review, absorbable im-
plants for the fixation of fractures. J. Bone Joint Surg.with primarily lamellar bone. Additionally, the torsional
73A:148–152; 1991.strength of the ulnae were comparable to the strength of
11. Constantino, P. D.; Friedman, C. D. Synthetic bone graft sub-the intact ulna after 12 weeks. The results of Cook et al.41
stitutes. Otol. Clin. N. Am. 27:1037–1074; 1994.
using rhBMP-7 with a collagen carrier are similar to those 12. Hench, L. L.; Andersson, O. H.; LaTorre, G. P. The kinetics
of Bostrom et al.39 and the current study using rhBMP-2 of bioactive ceramics part III: surface reactions for bioactive
with a polymer carrier. The local administration of rhBMP glasses compared with an inactive glass. Bioceramics 4:156–
162; 1991.unequivocally improves bone healing of large defects com-
13. Hollinger, J. O.; Schmitz, J. P.; Mixgala, J. W.; Hassler, C.pared to autograft, allograft, and demineralized bone matrix
An evaluation of two configurations of tricalcium phosphatein laboratory animals. Additionally, the new bone formed for treating craniotomies. J. Biomed. Mater. Res. 23:17–29;
within the defect achieves the mechanical strength of intact 1989.
established bone. 14. Holmes, R. E.; Bucholz, R. W.; Mooney, V. Porous hydroxy-
apatite as a bone-graft substitute in metaphyseal defects. J.In summary, this study showed that PDLLA provides a
Bone Joint Surg. 68A:904–911; 1986.viable osteoconductive matrix for infiltration of new bone
15. Klawitter, J.; Hulbert, S. Application of porous ceramics for
and a means to deliver rhBMP-2 to the defect site. It assem- the attachment of load bearing internal orthopedic applica-bles a mechanically robust construct within 4 weeks of tions. J. Biomed. Res. Symp. 2(1):161–229; 1971.
application within a rabbit radius CSD. The use of rhBMP 16. Schwartz, Z.; Braun, G.; Kohavi, D.; et al. Effects of hy-
droxyapatite implants on primary mineralization during ratwith a polymer carrier provides a viable option for the
tibial healing: biochemical and morphometric analyses. J.repair of bony defects while eliminating immunogenic and
Biomed. Mater. Res. 27:1029–1038; 1993.donor site morbidity associated with standard graft materi- 17. Heckman, J. D.; Boyan, B. D.; Aufdemorte, T. B.; Abbott,
als ( i.e., collagen, demineralized bone, autograft, and allo- J. T. The use of bone morphogenetic protein in the treatment
graft) . The robust mechanical strength demonstrated by of non-union in a canine model. J. Bone Joint Surg.
the regenerated bone matrix produced in the rhBMP-2 / 73A:751–763; 1991.
18. Marden, L. J.; Hollinger, J. O.; Chaudhari, A.; Turek, T.;PLA composite makes this graft substitute a potential fu-
Schaub, R. G.; Ron, E. Recombinant human bone morpho-ture option for many orthopedic procedures, including re-
genetic protein-2 is superior to demineralized bone matrix inpair of large segmental bone defects as a result of trauma,
repairing cranitomy defects in rats. J. Biomed. Mater. Res.
neoplasia, or infection. It may also be applicable in pros- 28:1127–1138; 1994.
thetic fixation, spinal arthrodesis, and fracture fixation. 19. Takaoka, K.; Nakahara, H.; Yoshikawa, H.; Mashuhara, K.;
Tsuda, H.; Ono, K. Ectopic bone induction on and in porous
The PLA and rhBMP-2 were provided as gifts by THM Biomedical Inc. and hydroxyapatite combined with collagen and bone morpho-
Genetics Institute, respectively. genetic protein. Clin. Orthop. Rel. Res. 234:250–254; 1988.
20. Urist, M. R. Bone: formation by autoinduction. Science
150:893–899; 1965.
21. Cook, S.; Baffes, G.; Wolfe, M.; Sampath, T.; Rueger, D.
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